Design of nanoparticles as drug carriers for cancer therapy

Cancer Genomics and Proteomics

Volumn 3, Issue 3-4, 2006, Pages 147-157

  Zhang, Jin ^a   Lan, Christopher Q ^a   Post, Michael ^b   Simard, Benoit ^b   Deslandes, Yves ^b   Hsieh, Tsung Han ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Cancer chemotherapy; Drug delivery; Magnetic nanohybrids; Nanoparticles; Polymer and liposome systems; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; LIPOSOME; NANOPARTICLE; PACLITAXEL; POLYMER; TAMOXIFEN;

CANCER CELL; CANCER RESEARCH; CANCER THERAPY; CELL TRANSPORT; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; NONHUMAN; REVIEW;

EID: 33746635660     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. American Cancer Society: Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society Inc., 2004.
2. NIH Cost of Illness Report to the U.S. Congress, 2005.
3. Christina RH and Danishefsky SJ: Complex target-oriented synthesis in the drug discovery process: a case history in the dEpoB series. J Org Chem 64: 8434-8456, 1999.
4. Kohler G and Milstein C: Continuous cultures of fuse cells secreting antibody of predefined specificity. Nature 75(suppl. 1): 381-394, 1975.
5. Langer R: Drug delivery and targeting. Nature 392: 5-10, 1998.
6. Kumar MN: Nano and microparticles as controlled drug delivery devices. J Pharmaceut Sci 3: 234-258, 2000.
7. Kumar MN, Kumar N and Domb AJ: Pharmaceutical polymeric controlled drug delivery systems. Adv Polymer Sci 160: 45-117, 2000.
8. Kreuter J: Nanoparticles: Colloidal Drug Delivery Systems. New York, Marcel Dekker, 1994.
9. Brigger I, Dubernet C and Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 54: 631-651, 2002.
10. Grossfeld GD, Carrol PR and Lindeman N: Thrombospondin-1 expression in patients with pathologic state T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis and tumor progression. Urology 59: 97-102, 2002.
11. Jones A and Harris AL: New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer Sci American 4: 209-217, 1998.
12. Yamaura H and Sato H: Quantitative studies on the developing vascular system of rat hepatoma. J Natl Cancer Inst 53: 1229-1240, 1974.
13. Skinner SA, Tutton PJ and O'Brien PE: Microvascular architecture of experimental colon tumors in the rat. Cancer Res 50: 2411-2417, 1990.
14. Maeda H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41: 189-207, 2001.
15. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Delivery Rev 46: 149-168, 2001.
16. Baban D and Seymour LW: Control of tumor vascular permeability. Adv Drug Delivery Rev 34: 109-119, 1998.
17. Seymour LW: Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187, 1992.
18. Hori K, Suzuki M, Tanda S and Saito S: Characterization of heterogeneous distribution of tumor blood flow in the rat. Jpn J Cancer Res 82: 109-117, 1991.
19. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051, 1987.
20. Links M and Brown R: Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Exp Rev Mol Med 1: 1-21, 1999.
21. Reynolds AR, Moghimi SM and Hodivala-Dilke K: Nanoparticle-mediated gene delivery to tumor vasculature. Trends Mol Med 9: 2-4, 2003.
22. Torchilin VP, Zhou F and Huang L: pH-sensitive liposomes. Liposome Res 3: 201-255, 1993.
23. Heuser LS and Miller FN: Differential macromolecular leakage from the vasculature of tumors. Cancer 57: 461-464, 1986.
24. Hori K, Suzuki M, Tanda S and Saito S: In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 81: 279-288, 1990.
25. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP and Jain RK: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95: 4607-4612, 1998.
26. Yuan F, Dellian M, Fukumura D, Leuning D and Berk DD: Vascular permeability in a human tumor xenograft: molecular size dependence and cut-off size. Cancer Res 55: 3752-3756, 1995.
27. Unezaki S, Maruyama K, Hosoda JI, Nagae I, Koyanagi Y, Nakata M, Ishida O, Iwatsuru M and Tsuchiya S: Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharmaceut 144: 11-17, 1996.
28. Langer R: Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc Chem Res 33: 94-101, 2000.
29. Johnson OL, Cleland JL, Lee HJ, Charmis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJS and Putney SD: A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med 3: 795-799, 1996.
30. Bangham AD and Mason WT: Anaesthetics may act by collapsing pH gradients. Anesthesiology 53: 135-141, 1980.
31. Umezawa F and Eto Y: Liposome targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Commun 153: 1038-1044, 1988.
32. Wang JY, Xu YR, Huang K and Sun LY: Proliposome targeting to rabbit brain tissue. J Pharm Pharmacol 47: 1053-1054, 1995.
33. Mora M, Sagrista ML, Trombetta D, Bonina FP, De Pasquale A and Saija A: Design and characterization of liposomes containing long-chain N-acylpes for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res 19: 1430-1438, 2002.
34. Zhang Y, Lee Jeong, Boado H and Pardridge RJ: Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 4: 183-194, 2002.
35. Kirsh R, Bugleski PJ and Poste G: Drug delivery to macrophages for the therapy of cancer and infectious diseases. In: Biological Approaches to the Controlled Delivery of Drugs. Juliano RL (ed.). The New York Academy of Sciences, New York, pp. 141-154, 1987.
36. Scherphof GL: In vivo behavior of liposomes. In: Targeted Drug Delivery. Juliano RL (ed.). Springer, Berlin, New York, pp. 285-300, 1999.
37. Fattal E, Rojas J, Youssef M, Couvreur P and Andremont A: Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob Agents Chemother 35: 770-772, 1991.
38. Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A and Gasco MR: Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 175: 185-193, 1998.
39. Cavalli R, Bocca C, Miglietta A, Caputo O and Gasco MR: Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. STP Pharma Sci 9: 183-189, 1999.
40. Schwarz C and Mehnert W: Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization. J Microencapsulation 16: 205-213, 1999.
41. Schwarz C, Mehnert W and Lucks JS: Solid lipid nanoparticles (SLN) for controlled drug-delivery: production, characterization and sterilization. J Controlled Release 30: 83-96, 1994.
42. Muller RH, Mehnert W and Lucks JS: Solid lipid nanoparticles (SLN) - an alternative colloidal carrier system for controlled drug-delivery. Eur J Pharmaceut Biopharmaceut 41: 62-69, 1995.
43. Storm G, Belliot SO, Daemen T and Lasic DD: Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17: 31-48, 1995.
44. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P and Speiser P: Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31: 331-332, 1979.
45. Sharma A and Sharma US: Liposomes in drug delivery: progress and limitations. Int J Pharmaceut 154: 123-140, 1997.
46. Yoo HS, Lee KH and Oh JE: In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Controlled Release 68: 419-431, 2000.
47. Chorny M, Fishbein I and Golomb G: Drug delivery systems for the treatment of restenosis. Crit Rev Therapeut Drug Carrier Systems 17: 249-284, 2000.
48. Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 56: 1649-1659, 2004.
49. Brigger I, Dubernet C and Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 54: 631-651, 2002.
50. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A and Ghosh PK: Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharmaceut 202: 1-10, 2002.
51. Storm G, Belliot SO, Daemen T and Lasic D: Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Delivery Rev 17: 31-48, 1995.
52. Duncan R: Polymer-Drug Conjugates: Targeting, Handbook of Anticancer Drug Development. Budman D, Calvert H and Rowinsky E (eds.). Lippincott, Williams & Wilkins, pp. 239-260, 2003.
53. Jain RK: Transport of molecules, particles and cells in solid tumors. Ann Rev Biomed Engineer 1: 241-263, 1999.
54. Barbe C, Bartlett J, Kong L, Finnie K, Lin HQ, Larkin M, Calleja S, Bush A and Calleja G: Silica particles: a novel drug-delivery system. Adv Materials 16: 1959-1966, 2004.
55. Bauer LA, Birenbaum NS and Meyer GJ: Biological applications of high aspect ratio nanoparticles. J Materials Chem 14: 517-526, 2004.
56. Ozkan M: Quantum dots and other nanoparticles: what can they offer to drug delivery? Drug Discovery Today 9: 1065-1071, 2004.
57. Jen CP, Chen YH, Fan CS, Yeh CS, Lin YC, Shieh DB, Wu CL, Chen DH and Chou CH: A nonviral transfection approach in vitro: the design of a gold nanoparticle vector joint with microelectromechanical systems. Langmuir 20: 1369-1374, 2004.
58. Kam NWS, Jessop TC and Wender HJ: Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J Am Chem Soc 126: 6850-6851, 2004.
59. Kriven WM, Kwak SY, Wallig MA and Choy JH: Bioresorbable nanoceramics for gene and drug delivery. MRS Bulletin 29: 33-37, 2004.
60. Soppimatha KS, Aminabhavi TM, Kulkarnia AR and Rudzinskib WE: Biodegradable polymeric nanoparticles as drug delivery devices. J Controlled Release 70: 1-20, 2001.
61. He P, Davis SS and Ilium L: Chitosan microspheres prepared by spray drying. Int J Pharmaceut 187: 53-65, 1999.
62. Bittner B, Mader K and Kroll C: Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J Controlled Release 59: 23-32, 1999.
63. Zhang J, Worley J, Denommee S, Kingston C, Jakubek ZJ, Deslandes Y, Post M and Simard B: Synthesis of metal alloy nanoparticles in solution by laser irradiation of metal powder suspension. J Phys Chem B 107: 6920-6923, 2003.
64. Zhang J, Chow GM, Lawrence SH and Feng CR: Nanostructured Ni films by polyol electroless deposition. Materials Phys Mech 1: 11-14, 2000.
65. Zhang J and Chow GM: Polyol process and magnetization properties of nanostructured NiCo films. J Appl Phys 88: 2125-2129, 2000.
66. Zhang Y, Kohler N and Zhang M: Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23: 1553-1561, 2002.
67. Zhang Y, Sun C, Kohler N and Zhang M: Self-assembled coatings on individual monodispersed magnetite nanoparticles for efficient intracellular uptake. Biomed Microdevices 6: 33-40, 2004.
68. Rolland A: Advanced Gene Delivery: From Concepts to Pharmaceutical Products. Harwood, Amsterdam. 1999.
69. Azzam T and Domb AJ: Current development in gene transfection agents. Curr Drug Delivery 1: 165-193, 2004.
70. Forbes ZG, Yellen BB, Barbee KA and Friedman G: An approach to targeted drug delivery based on uniform magnetic fields. IEEE Tran Mag 39: 3372-3377, 2003.
71. Gerlowski LE and Jain RK: Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31: 288-299, 1986.
72. Widder KJ, Senyei AE and Ranney DF: Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. In: Advances in Pharmacology and Chemotherapy. Gavattini S, Goldin A, Howking F, Kopin IJ and Schnitzer RJ (eds.). New York, NY, Academic Press, pp. 213-239, 1997.
73. Morimoto Y, Okumura M, Sugibayashi K and Kato Y: Preparation and magnetic guidance of magnetic albumin microspheres for site specific drug delivery in vivo. J Pharm Dyn 4: 624-631, 1981.
74. Gupta PK and Hung CT: Magnetically controlled targeted chemotherapy. In: Microspheres and Regional Cancer Therapy. Willmott N and Daly J (eds.). CRC Press, Boca Raton, FL, pp. 71-116, 1994.
75. Gallo JM, Gupta PK, Hung CT and Perrier DG: Evaluation of drug delivery following the administration of magnetic albumin microspheres containin adriamycin to the rat. J Pharm Sci 78: 190-194, 1989.
76. Devineni D, Klein-Szanto A and Gallo JM: Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J Neuro-Onc 24: 143-152, 1995.
77. Alksne JF, Fingerhut A and Rand R: Magnetically controlled metallic thrombosis of intracranial aneurysms. Surgery 60: 212-218, 1996.
78. Hilal SK, Michelsen WJ, Driller J and Leonard E: Magnetically guided devices for vascular exploration and treatment. Radiology 113: 529-534, 1974.
79. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW and Huhn D: Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56: 4694-4701, 1996.
80. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dorken B, Herrmann F, Gurtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W and Huhn D: Clinical experiences with magnetic drug targeting: a phase I study with 40-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56: 4686-4693, 1996.
81. Alexiou C, Schmidt A, Klein R, Hulin P, Bergemann C and Arnold W: Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J Mag Mag Mater 252: 363-366, 2002.
82. Gu HW, Ho PL, Tsang KWT, Wang L and Xu B: Using biofunctional magnetic nanoparticles to capture vancomycin-resistant enterococci and other gram-positive bacteria at ultralow concentration. J Am Chem Soc 125: 15702-15703, 2003.
83. Brusentsov NK, Nikitin LV, Brusentsova TN, Kuznetsov AA, Bayburtskiy FS, Shumakov LI and Jurchenko NY: Magnetic fluid hyperthermia of the mouse experimental tumor. J Mag Mag Mater 252: 378-380, 2002.
84. Molday RS and Mackenzie D: Immunospecific ferromagnetic iron-dextran reagents for the labelling and magnetic separation of cells. J Immun Meth 52: 353-367, 1982.
85. Suzuki M, Shinkai M, Kamihira M and Kobayashi T: Preparation and characteristics of magnetite-labelled antibody with the use of poly(ethylene glycol) derivatives. Biotech Appl Biochem 21: 335-345, 1995.
86. Yoshimoto T, Mihama T, Takahashi K, Saito Y, Tamaura Y and Inada Y: Chemical modification of enzymes with activated magnetic modifier. Biochem Biophys Res Comm 145: 908-914, 1987.
87. Kirsh R, Bugleski PJ and Poste G: Drug delivery to macrophages for the therapy of cancer and infectious diseases. In: Biological Approaches to the Controlled Delivery of Drugs. Juliano RL (ed.). The New York Academy of Sciences, New York, pp. 141-154, 1987.
88. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J and Kobayashi T: Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 87: 1179-1183, 1996.
89. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y and Murakami T: Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 17: 309-315, 2000.
90. Sakamoto A and Ido T: Liposome targeting to rat brain: effect of osmotic opening of the blood-brain barrier. Brain Res 629: 171-175, 1993.
91. Kniesel U and Wolburg H: Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 20: 57-76, 2000.
92. Eid T, Brines ML, Cerami A, Spencer DD, Kim JH, Schweitzer JS, Ottersen OP and de Lanerolle NC: Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. J Neuropathol Exp Neurol 63: 73-83, 2004.
93. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK and Vyasa SP: RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharmaceut 261: 43-55, 2003.
94. Lu Y, Yin Y, Mayers BT and Xia Y: Modifying the surface properties of superparamagnetic iron oxide nanoparticles through a sol-gel approach. Nano Lett 2: 183-186, 2002.
95. Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim HW, Lee KH, Park SB, Lee JK and Cho MH: Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicolog Sci 89: 338-347, 2006.
96. Zhang J, Post M, Veres T, Jakubek ZJ, Guan JW, Wang DS, Normandin F, Deslandes Y and Simard B: Laser-assisted synthesis of superparamagnetic Fe@Au core-shell nanoparticles. J Phys Chem B 10: 7122-7128, 2006.